Cases & investigations

Cases & investigations

Immunovant, Inc.

Kaskela Law LLC is investigating Immunovant, Inc. (Nasdaq: IMVT) on behalf of the Company’s stockholders.

On June 1, 2021, shares of Immunovant’s common stock declined $5.76 per share, or 38% in value, after the Company reported its financial and operational results for the Quarter and Fiscal Year ended March 31, 2021, and disclosed that its Chief Medical Officer (“CMO”), Rita Jain, M.D.,  had stepped down “to pursue another opportunity.”  Notable, Dr. Jain only recently joined the Company as its CMO, in January 2021.

The investigation seeks to determine whether Immunovant and the company’s executive officers and/or directors violated the securities laws in connection with statements made to investors, and whether Immunovant investors have been harmed as a result of such actions.

Immunovant investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by completing the information form on this page, for additional information about the investigation and their legal rights and options.

Submit Your Information

  • Approximate Loss Suffered